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Malaria  is a mosquito  borne  infectious  disease  caused  by  protozoa  of  genus  Plasmodium.  There  are  ﬁve
species  of  Plasmodium  that  are  found  to  infect  humans.  Plasmodium  falciparum  can  cause  severe  malaria
leading  to higher  morbidity  and  mortality  of malaria  than  the  other  four species.  Antimalarial  resistance
is  the  major  obstacle  to  control  malaria.  Meﬂoquine  was used  in combination  with  Artesunate  for  uncom-
plicated  P.  falciparum  in South  East  Asia  and it has developed  and  established  meﬂoquine  resistance  in this
region.  Here,  gel-enhanced  liquid  chromatography/tandem  mass  spectrometry  (GeLC–MS/MS)-based
proteomics  and  label-free  quantiﬁcation  were  used  to explore  the protein  proﬁles  of meﬂoquine-sensitive
and  -induced  resistant  P. falciparum.  A Thai  P.  falciparum  isolate  (S066)  was  used  as  a model  in this
research.  Our data  revealed  for  the  ﬁrst time  that 69  proteins  exhibited  at least  2-fold  differences  in  their
expression  levels  between  the  two parasite  lines.  Of these,  36 were  up-regulated  and  33 were  down-
regulated  in  the  meﬂoquine-resistant  line compared  with  the  meﬂoquine-sensitive  line.  These  ﬁndings
are  consistent  with  those  of  past  studies,  where  the  multidrug  resistance  protein  Pgh1 showed  an  up-
regulation  pattern  consistent  with  that  expected  from  its  average  3-copy  pfmdr1  gene number.  Pgh1
and  eight  other  up-regulated  proteins  (i.e.,  histo-aspartyl  protease  protein,  exportin  1,  eukaryotic  trans-
lation  initiation  factor  3 subunit  8, peptidyl-prolyl  cis-trans  isomerase,  serine  rich  protein  homologue,
exported  protein  1, ATP synthase  beta chain  and  phospholipid  scramblase  1)  were  further  validated  for
their expression  levels  using  reverse  transcriptase  quantitative  real-time  PCR.  The  data  support  the up-
regulation  status  in  the meﬂoquine-resistant  parasite  line of  all the  candidate  genes  referred  to above.
Therefore,  GeLC–MS/MS-based  proteomics  combined  with  label-free  quantiﬁcation  is  a reliable  approach
for exploring  meﬂoquine  resistance  biomarkers  in  P.  falciparum.  Identiﬁcation  of these proteins  leads  to
better  understanding  of meﬂoquine  resistant  mechanisms  in malaria  parasites.
ublis©  2015  The  Authors.  P
. Introduction
Malaria is a life-threatening disease caused by protozoa called
lasmodium. The Plasmodium transmits to human by the infected
emale Anopheles mosquitoes. According to WHO  report in 2012,
alaria infects 207 million people each year around the world,ausing more than 627,000 deaths, especially in children under
ve years old in sub-Saharan Africa [1]. Despite the numerous pub-
ished studies that have reported effective approaches for malaria
∗ Corresponding author. Tel.: +66 23549100.
E-mail addresses: onrapak.rea@mahidol.ac.th (O. Reamtong),
allika.imw@mahidol.ac.th (M.  Imwong).
ttp://dx.doi.org/10.1016/j.ijms.2015.09.009
387-3806/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).hed  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
diagnosis and treatment, parasite resistance to multiple drugs has
ensured that malaria remains a global health problem. Research
has shown that most drug-resistant Plasmodium falciparum para-
sites originated in Southeast Asia [2]. Meﬂoquine was introduced
as a ﬁrst-line malaria treatment in Thailand in 1984. Unfortu-
nately, meﬂoquine-resistant parasites developed within 6 years
of its use. The combination therapy of artemisinin derivatives
and meﬂoquine has been recommended to improve the efﬁcacy
of anti-malarial treatment in South East Asia [3,4]. Although this
drug combination has proved to be highly effective for malaria
treatment, the molecular mechanisms of meﬂoquine resistance in
malaria parasites remain unclear.
A point mutation in the P-glycoprotein gene homologue
(pfmdr1) at codon 86 (Asn to Tyr) was reported to effect
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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hloroquine and meﬂoquine susceptibility in P. falciparum in vitro
5,6]. However, ampliﬁcation and overexpression of pfmdr1 pro-
ided stronger evidence regarding the association with meﬂoquine
esistance from both in vitro culture and parasites from patients
7,8]. Pfmdr1 is a homologue of the human P-glycoprotein, an
denosine triphosphate (ATP)-Binding Cassette (ABC) transporter
amily member. ABC transporters are transmembrane proteins that
ranslocate compounds across membranes using the energy from
TP. An increased meﬂoquine efﬂux was observed in meﬂoquine-
esistant P. falciparum resulting in alteration of the meﬂoquine
ccumulated in the parasite cell [9]. Nonylphenol ethoxylate
NP30) is a potential P. falciparum P-glycoprotein substrate and
rug efﬂux inhibitor. According to in vitro assay results, NP30 was
ble to sensitize meﬂoquine resistance in more than 80% of the
. falciparum parasites that were tested. This ﬁnding refers to the
eﬂoquine efﬂux activity related to P-glycoprotein [10]. Several
tudies suggested that the increase in pfmdr1 copy number is asso-
iated with meﬂoquine resistance. Moreover, the evidences in vitro
nd in vivo have shown that the pfmdr1 gene ampliﬁcation has a
ajor role in the development of meﬂoquine resistance [8,11,12].
fmdr1 gene ampliﬁcation is better predictor for meﬂoquine resis-
ance than pfmdr1 polymorphisms. Therefore, the mechanisms
f meﬂoquine resistance could be multifactorial traits that act
ogether and result in expression of the resistant phenotype. How-
ver, only 58% in vitro and 63% in vivo of meﬂoquine resistant P.
alciparum showed the association with the increase of gene copy
umber [8]. Therefore, there are other factors involved in mecha-
isms of meﬂoquine resistance.
Accordingly, this study attempted to explore other molecular
arkers of meﬂoquine resistance using mass spectrometry-based
roteomics, with the aim of obtaining a better understanding of
eﬂoquine resistant mechanisms in P. falciparum parasites. To
ccomplish this aim, the Thai P. falciparum isolate S066 was used
s a model parasite for this research. In 2009, the resistant line
as developed by exposure of the culture parasites to stepwise
ncreasing in meﬂoquine concentration. The sensitive line was
lso maintained in continuous culture in the same condition with
esistant line. Genotyping with available genetic markers includ-
ng msp1, msp2, glurp, and ten microsatellite markers revealed
hat these two lines contained the same single genotype. This
ulture-adapted meﬂoquine resistant P. falciparum line has an
mpliﬁed pfmdr1 locus with an average 3 copies of pfmdr1 [11].
he above study [11] was based on meﬂoquine-sensitive and
resistant P. falciparum that originated from the same strain, mean-
ng there should be minimal background genetic variation between
hese two lines. Recently, several techniques have become avail-
ble for performing proteomic experiments. Gel-enhanced liquid
hromatography/tandem mass spectrometry (GeLC–MS/MS) is an
ncomplicated and powerful proteomic technique used for study-
ng biological samples. In GeLC–MS/MS, a protein lysate from a
iological sample is separated by sodium dodecyl sulphate poly-
crylamide gel electrophoresis (SDS-PAGE) and each gel lane is
liced into small pieces, in-gel digestion is performed, and the
reated sample is analyzed by liquid chromatography (LC–MS/MS).
he database search results for all the slices are combined yield-
ng global protein identiﬁcation and quantiﬁcation. GeLC–MS/MS
an be used in combination with a label-free approach to obtain
rotein quantiﬁcation information. The label-free method involves
traightforward sample preparation with no extra costs and the
echnique is not time consuming. Additionally, label-free methods
an be multiplexed to a higher degree than unlabeled methods,
nd can even be used for data that has already been acquired.
he exponentially modiﬁed protein abundance index (emPAI)
pproach is a spectral counting label-free quantiﬁcation approach.
t was developed by Ishihama and co-workers [13,14] to mea-
ure the protein composition of sample solutions. Label-free emPAIMass Spectrometry 391 (2015) 82–92 83
quantitative proteomics has been proved successful for quantiﬁca-
tion of Aspergillus fumigatus secretomes at different temperatures
[15], and quantiﬁcation of mannose-binding proteins from normal
donor and hepatocellular carcinoma patient sera [16]. Hence, the
goal of this research was to conduct a comparative proteomic anal-
ysis of meﬂoquine-sensitive and -resistant P. falciparum parasites to
gain better insight into meﬂoquine resistant mechanisms using the
GeLC–MS/MS approach combined with emPAI label-free protein
quantitation.
2. Materials and methods
2.1. P. falciparum culture
Meﬂoquine-sensitive or -resistant P. falciparum isolate S066
parasites were grown at 37 ◦C in O+ erythrocytes washed in
RPMI 1640 medium (Invitrogen, MA,  USA). Media were supple-
mented with 0.5% Albumax II (Gibco, New Zealand), 5 g/mL of
hypoxanthine (Sigma, USA) and 50 g/mL of gentamicin sulphate
(Government Pharmaceutical Organization, Thailand). Parasites
were continuously cultured in 5% CO2 to obtain a high proportion
of ring-forms, after which the medium was discarded. Infected red
blood cells were resuspended in 5% sorbitol solution (Sigma, USA)
and incubated for 20 min  at 37 ◦C. The cells were then washed in
RPMI medium and further cultured. The sorbitol synchronization
was repeated again after 32 h to ensure a high level of synchrony in
the culture. Parasitaemias and culture progression were monitored
every 24 h by Giemsa staining (Sigma, USA). When the percent-
age parasitaemia reached 5% and schizont-stage parasites were
present, the culture was harvested.
2.2. Parasite protein preparation
To reduce contamination from red blood cell proteins, P. falcip-
arum parasites were released from infected erythrocytes by lysis in
0.05% saponin (Sigma, USA) in phosphate-buffered saline (Sigma,
USA) for 5 min  at 4 ◦C, followed by centrifugation at 1000 × g at 4 ◦C
for 5 min. Parasite pellets were washed with PBS three times. Pel-
lets were snap-frozen in liquid nitrogen and stored at −80 ◦C until
use. Each parasite pellet was  resuspended in 100 L lysis buffer (1%
SDS, 1% Triton X, 0.5% NaCl), a protease cocktail inhibitor (Sigma,
USA) was  added, and the preparation was sonicated on ice with
four 10-s pulses (Cole-Parmer, IL, USA). The protein concentration
of the lysate was 14 g/L  using the Bradford protein assay with
BSA as a standard (Thermo, USA).
2.3. SDS-PAGE
The 30 L of protein from the meﬂoquine-sensitive and -
resistant P. falciparum lines was denatured by heating for 5 min at
95 ◦C in sample buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
1% -mercaptoethanol and bromophenol blue) (GE Healthcare,
UK). Both of the denatured protein samples were loaded onto 10%
SDS-polyacrylamide gels. A constant electric current was applied to
separate the proteins until the blue dye front reached the bottom
of the gel. To detect the protein bands, the SDS-polyacrylamide gels
were stained with Coomassie blue G-250 (Biorad, CA, USA). After
that, the gel was  de-stained in 45% methanol and 10% acetic acid in
deionized water, until clear bands were visible. Each gel lane was
trimmed into 28 pieces and kept at −20 ◦C until use.
2.4. In-gel digestionGel pieces were de-stained prior to tryptic digestion. Acetoni-
trile (50%) was added to the gel followed by incubation for 15 min.
The colourless gel pieces were then dehydrated by acetonitrile and
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llowed to dry completely in a fume hood. To rehydrate the gel
ieces, trypsin solution at a concentration of 0.02 mg/mL  in 50 mM
mmonium bicarbonate (Sigma, USA) was added to the tubes and
ach gel piece was incubated at 37 ◦C overnight. Peptides were
xtracted by addition of acetonitrile and the solution was  shaken
or 15 min. The supernatant was collected and the peptide mix-
ures were completely dried by a speed-vac (Eppendorf, Hamburg,
ermany). The samples were stored at −20 ◦C prior to mass spec-
rometric analysis.
.5. NanoLC–MS/MS analysis
Each tryptic-digested fraction was resuspended in 0.1% formic
cid containing 2% acetonitrile and then introduced to an Ulti-
ate 3000 nano-LC system (Dionex, Surrey, UK) coupled with a
icrOTOF-Q (Bruker Daltonics, Bremen, Germany). Separation was
one on a 58 min  gradient, with a ﬂow rate of 200 nL/min. Mobile
hase A was 2% acetonitrile and 0.1% formic acid in HPLC grade
ater and mobile phase B was 0.1% formic acid in HPLC grade
cetonitrile. Data acquisitions were controlled using Hystar soft-
are (Bruker Daltonics, Bremen, Germany). MS  and MS/MS spectra
overed the mass range of m/z 400–2000 and m/z  50–1500, respec-
ively.
.6. Data analysis
LC–MS/MS data ﬁles were converted to a mascot generic ﬁle
.mgf) format using DataAnalysisTM software, version 3.4. The .mgf
les were merged using Mascot daemon 2.4 software and searched
sing Mascot version 2.4.1 (Matrix Science, London, UK) against
he NCBInr database (16 April 2015), which contained 66,387,522
equences entries. P. falciparum was set as the taxonomy ﬁlter.
issed cleavage was set to 1, the peptide tolerance was set to
.2 Da, and the tandem MS  tolerance was set to 0.6 Da. Variable
odiﬁcations were set to include methionine oxidation and cys-
eine carbamidomethylation. We  searched each identiﬁed peptide
gainst the NCBI database. Quantiﬁcation was performed using
mPAI provided by Mascot [13]. The emPAI values in this report
ere the mean of three biological replications. Hits with a mini-
um  of at least two peptides and a minimum mascot ion score of
0 were chosen as true identiﬁcation for further analysis. PANTHER
oftware was used to classify the proteins identiﬁed according to
ene ontology [17].
.7. RNA extraction and cDNA synthesis
Total RNA was isolated from meﬂoquine-sensitive and -resistant
. falciparum using TRI-reagent (Ambion Inc., Austin, TX, USA), fol-
owing the manufacturer’s protocol. Brieﬂy, after red blood cell
elease, parasite pellets were suspended in 1 mL  of TRI-reagent and
hen incubated at room temperature for 15 min. Nucleic acids were
ecovered from the lysates by adding 200 L of chloroform (Sigma,
O,  USA) followed by centrifugation at 12,000 × g for 15 min  at
◦C. The aqueous layer was transferred to a clean microcentrifuge
ube and isopropanol was added to precipitate the nucleic acids.
he pellet was collected by centrifugation (12,000 × g, 10 min, 4 ◦C),
ashed with 75% ethanol, air dried, and resuspended in 50 L of
Nase-free water. To remove contaminating DNA, DNase I (Qiagen,
etherlands) was added to the RNA solution and it was incubated
t 37 ◦C for 1 h. Addition of 50 mM of EDTA, followed by incubation
t 65 ◦C for 10 min  was done to inactivate DNase I. The 260/280 nm
bsorbance ratio was used to assess the purity of the DNA and
NA using a Nanodrop 2000 spectrophotometer (Thermo Scientiﬁc,
ilmington, DE, USA). The RevertAidTM First Strand cDNA Synthe-
is Kit (Fermentas, Thermo Fischer Scientiﬁc Inc., USA) was  used for
DNA synthesis. RNA from the meﬂoquine-sensitive and -resistantFig. 1. Coomassie blue stained gels of meﬂoquine-sensitive and meﬂoquine-
resistant P. falciparum proteins separated by SDS-PAGE.
P. falciparum,  an oligo(dT)18 primer, dNTPs, 10× ﬁrst strand buffer
and RevertAidTM Reverse Transcriptase were mixed and incubated
at 42 ◦C for 1 h. For inactivation, the reaction was  heated to 70 ◦C
for 5 min. The cDNA was  kept at −20 ◦C until use.
2.8. Quantitative real-time PCR (qPCR)
A SYBR-Green ﬂuorescence-based qPCR assay was used to deter-
mine the expression levels of nine candidate markers in the
meﬂoquine-sensitive and -resistant P. falciparum lines using an
ABI Prism 7500 Thermal Cycler (Applied Biosystems, Foster City,
CA, USA). The relevant mRNA sequences were retrieved from the
NCBI database. Gene-speciﬁc primers were designed using Primer
Express software (Applied Biosystems). The following primers
were synthesized for the nine candidate markers: multidrug resis-
tance protein Pgh1, histo-aspartyl protease (HAP) protein, exportin
1, eukaryotic translation initiation factor 3 subunit 8, peptidyl-
prolyl cis-trans isomerase, serine rich protein (SERP) homologue,
exported protein 1 (Exp-1), ATP synthase beta chain and phospho-
lipid scramblase 1. For the real-time qPCR assays, 5 L of 2× Power
SYBR® Green PCR Master Mix  (Applied Biosystems), 10 nM of each
nal of 
p
r
T
a
t
t
c
e
f
t
d
r
w
c
3
3
f
r
c
m
c
z
o
t
a
h
c
s
A
F
s
c
o
1
r
t
d
m
m
d
i
P
i
b
t
a
p
r
t
h
c
f
v
r
m
i
a
pO. Reamtong et al. / International Jour
rimer, and 0.5 L of cDNA were prepared to achieve a 10 L ﬁnal
eaction volume. The PCR conditions are shown in Supplemental
able 4. In every experiment, the beta-tubulin reference gene was
lso ampliﬁed. The average CT value was calculated. Relative quan-
iﬁcation analysis used the comparative CT (2−CT) method [18]
o determine the mRNA expression level. The qRT-PCR analyses
omprised three separate biological replicates.
The expression levels of the nine candidate markers were
xamined by culturing the meﬂoquine-sensitive and -resistant P.
alciparum under a sublethal meﬂoquine dose. During in vitro cul-
ure of P. falciparum,  a meﬂoquine concentration at a sublethal
ose (IC5) was added to the culture media. When the parasitaemia
eached 5% and schizont-stage parasites were present, the culture
as harvested. RNA extraction, cDNA synthesis, and reverse trans-
riptase qPCR were performed as described above.
. Results and discussion
.1. Proteomic proﬁling of meﬂoquine-sensitive and -resistant P.
alciparum using GeLC–MS/MS
According to in vitro culture of malaria parasite, meﬂoquine-
esistant P. falciparum exhibited delay of stage development
ompared to sensitive parasite. The resistant line took approxi-
ately 3 h slower than the sensitive line to complete erythrocytic
ycle. The overall parasite morphology including amount of hemo-
oin in those two lines was not signiﬁcant difference. Process
f freezing and thawing from liquid nitrogen were not affect to
he resistant characteristic of the meﬂoquine-resistant P. falcip-
rum because IC50 of the resistant line was remained 10-fold
igher than the sensitive line and the resistant line still carried 3
opies of pfmdr1 gene. The schizont proteomes of the meﬂoquine-
ensitive and -resistant P. falciparum were separated by SDS-PAGE.
 Coomassie blue stained gel of such a preparation is shown in
ig. 1.
Each lane from a gel was cut into 28 pieces and each piece was
ubject to mass spectrometry. SDS-PAGE of three biological repli-
ates is presented in Supplemental Figure 1. Protein identiﬁcation
f three biological replicates is presented in Supplemental Table
. Total 469 proteins were similarly found in all three biological
eplicates. The emPAI values were applied for protein quantiﬁca-
ion. A matrix plot of emPAI values of three biological replicates is
emonstrated in Fig. 2.
Based on the matrix plot, all three biological replicates of
eﬂoquine-sensitive P. falciparum (MQS1, MQS2 and MQS3) and
eﬂoquine-resistant P. falciparum (MQR1, MQR2 and MQR3)
emonstrated the correlation among their groups. When compar-
ng emPAI between meﬂoquine-sensitive and meﬂoquine-resistant
. falciparum, there was deviation of emPAI value from the linear-
ty corresponded to the differences of protein expression between
oth parasites. Protein quantiﬁcation and Mascot information of
hree biological replicates are shown in Supplemental Tables 2
nd 3, respectively. Due to protein quantiﬁcation, a total of 400
roteins (86%) were common to both meﬂoquine-sensitive and -
esistant P. falciparum.  The common proteins identiﬁed between
he meﬂoquine-sensitive and -resistant P. falciparum were mostly
ousekeeping proteins (e.g., transcription factors, histones and
ytoskeletal proteins). Nevertheless, 69 proteins had at least 2-
old differences in their expression levels according to the emPAI
alues and 36 proteins were up-regulated and 33 were down-
egulated in the meﬂoquine-resistant parasites compared to their
eﬂoquine-sensitive counterparts. Gene ontology cluster analysis
n the PANTHER database was used to examine the 36 up-regulated
nd 33 down-regulated proteins according to their biological
rocesses (Fig. 3).Mass Spectrometry 391 (2015) 82–92 85
The up-regulated proteins were classiﬁed into the following
seven groups: 3% biological regulation, 3% cellular component orga-
nization, 4% cellular process, 7% localization, 13% metabolic process,
2% in response to stimulus, and 68% were of unknown function.
When considering the “in response to stimulus” group proteins,
meﬂoquine is potentially the stimulating factor in the culture-
adapted meﬂoquine-resistant parasites because such parasites
possibly respond to the stress conditions generated by meﬂoquine.
In the meﬂoquine-resistant strain, proteins in the “biological reg-
ulation” group were also up-regulated. Alterations in biological
regulation processes may  be important for modulating the resis-
tance phenotype of the malaria parasite. In contrast, classiﬁcation
of the down-regulated proteins sorted them into the ﬁve following
groups: 5% cellular component organization, 8% cellular process,
3% localization, 31% metabolic process, and 53% were of unknown
function. The “metabolic process” and “cellular process” group
proteins are involved in resource management and general func-
tions of the parasite. Both groups had lower expression levels in
meﬂoquine-resistant P. falciparum.  Interestingly, examination of
the in vitro culture showed that the meﬂoquine-resistant parasite
line developed blood stages slower than the meﬂoquine-sensitive
line. This ﬁnding might result from down-regulation of metabolic
and cellular processes. Moreover, down-regulation of these general
processes is consistent with the many scientiﬁc publications on the
reduced ﬁtness of drug-resistant malaria parasites. Drug-resistant
parasite genotypes are likely to be less ﬁt than their wild-type coun-
terparts (or congenic lines) and lower ﬁtness puts such parasites
at a survival disadvantage [19–21] under conditions of reduced
drug pressure. The lower ﬁtness of drug-resistant parasites proba-
bly results from the reduced activities of general cellular processes.
Parasite proteins with unknown functions were the major group in
both the up-regulated and down-regulated proteins.
Data for the up-regulated and down-regulated proteins from
meﬂoquine-resistant P. falciparum are provided in Tables 1 and 2.
Based on the up-regulated proteins illustrated in Table 1, the mul-
tidrug resistance protein Pgh1 is up-regulated 8.5-fold; this result
is consistent with the existence of three copies of the pfmdr1 gene
in the meﬂoquine-resistant parasite line.
This result also shows how effective GeLC–MS/MS-based pro-
teomics are when combined with emPAI label-free quantiﬁcation
at identifying and quantifying proteins from complex samples.
In addition, extracted ion chromatograms of a precursor ion of a
pfmdr1 peptide (FAAIDEFIESLPNKYDTNVGPYGK) at m/z  896.7 from
three biological replicates are demonstrated in Fig. 4. Based on
the correlated retention times in all chromatograms, meﬂoquine-
resistant parasite showed peak of pfmdr1 peptide while this
peak was absent in the meﬂoquine-sensitive parasite. This result
corresponded to the up-regulation of pfmdr1. Comparison of inten-
sities of precursor ions of pfmdr1 peptide at m/z 896.7 between
meﬂoquine-sensitive and meﬂoquine-resistant parasites was also
presented in Fig. 5. The intensity of m/z 896.7 precursor ions in
meﬂoquine-resistant parasite revealed higher abundance than in
meﬂoquine-sensitive parasite. This ﬁnding also referred to the
up-regulation of pfmdr1. The extracted ion chromatogram and
precursor ion intensity supported the ﬁnding from label-free quan-
tiﬁcation.
The up- and down-regulation data from label-free quan-
tiﬁcation also revealed several interesting protein markers for
meﬂoquine resistance. Some of them have known relationships
with drug resistance in other organisms. For example, HAP, which
has an aspartic-type endopeptidase activity, was  up-regulated in
the drug-resistant parasite. This enzyme is one of four essential
proteases in the P. falciparum food vacuole [22]. Plasmepsin I,
II, and IV and HAP are involved in haemoglobin degradation, a
major nutrient source for malaria parasites. Within the food vac-
uole, haemoglobin is degraded to peptides and is then exported to
86 O. Reamtong et al. / International Journal of Mass Spectrometry 391 (2015) 82–92
Fig. 2. A matrix plot of emPAI values of three biological replicates. MQS1, MQS2, MQS3, MQR1, MQR2 and MQR3 are meﬂoquine-sensitive P. falciparum 1, meﬂoquine-sensitive
P.  falciparum 2, meﬂoquine-sensitive P. falciparum 3, meﬂoquine-resistant P. falciparum 1, meﬂoquine-resistant P. falciparum 2 and meﬂoquine-resistant P. falciparum 3,
respectively.
Fig. 3. Classiﬁcation of differentially expressed proteins according to their biological processes. Left pie chart represents the gene ontology categories for genes up-regulated
in  meﬂoquine-resistant P. falciparum. Right pie chart represents the gene ontology categories for genes down-regulated in meﬂoquine-resistant P. falciparum.
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Table  1
Up-regulated proteins in meﬂoquine-sensitive and meﬂoquine-resistant P. falciparum.
Accession Protein Mass pI emPAI value Fold change
MQ sensitive MQ resistant
gi|124513520 Protein kinase 111,269 5.98 0.24 ± 0.02 0.86 ± 0.15 3.58
gi|3023709 Enolase 48,673 6.21 0.08 ± 0.02 0.81 ± 0.10 10.13
gi|8050813 Multidrug resistance
protein Pgh1
161,695 8.94 0.02 ± 0.00 0.17 ± 0.08 8.50
gi|124802886 tRNA pseudouridine
synthase D
116,647 5.96 0.42 ± 0.04 1.75 ± 0.23 4.17
gi|385236 Rhoptry protein 104,789 6.25 0.11 ± 0.05 0.27 ± 0.09 2.45
gi|4699811 Chain A, chloroquine binds
in  the cofactor binding site
of Plasmodium falciparum
lactate dehydrogenase
34,102 7.12 NDa 0.37 ± 0.04 NDa
gi|237665424 Rhoptry-associated protein
2
46,709 8.90 0.12 ± 0.05 0.26 ± 0.05 2.17
gi|37777722 Exported protein 1 13,399 9.66 0.24 ± 0.09 0.68 ± 0.13 2.83
gi|86171188 Histone h2a 14,114 10.29 1.09 ± 0.11 2.41 ± 0.27 2.21
gi|1172530 Plasmepsin-2 51,457 5.42 0.09 ± 0.02 0.23 ± 0.07 2.56
gi|124513738 Conserved Plasmodium
protein, unknown function
186,204 6.29 0.04 ± 0.01 0.18 ± 0.06 4.50
gi|124808181 HAP protein 51,661 8.04 0.23 ± 0.06 0.52 ± 0.11 2.26
gi|124806537 ATP synthase beta chain,
mitochondrial precursor
58,357 6.01 0.06 ± 0.02 0.13 ± 0.05 2.17
gi|124504723 Exportin 1 147,843 5.69 0.20 ± 0.04 0.73 ± 0.07 3.65
gi|86170934 Plasmodium falciparum
membrane protein pf12
precursor
39,409 8.69 0.10 ± 0.03 0.20 ± 0.02 2.00
gi|124802544 Phospholipid scramblase 1 32,997 8.10 0.05 ± 0.01 0.24 ± 0.09 2.80
gi|124512958 Hypothetical protein 16,515 4.08 0.23 ± 0.08 0.52 ± 0.13 2.26
gi|124806675 Conserved Plasmodium
protein
690,984 5.59 NDa 0.01 ± 0.00 NDa
gi|1262910 Cytidine triphosphate
synthetase
98,786 6.22 0.01 ± 0.00 0.04 ± 0.01 4.00
gi|124805548 Eukaryotic translation
initiation factor 3 subunit 8
115,941 5.26 0.03 ± 0.00 0.08 ± 0.03 2.67
gi|124803860 Peptidyl-prolyl cis-trans
isomerase
21,717 7.10 0.38 ± 0.02 0.91 ± 0.05 2.39
gi|237664980 Pf38-like hypothetical
protein
35,052 8.18 0.05 ± 0.01 0.11 ± 0.00 2.20
gi|124808108 Conserved Plasmodium
protein, unknown function
338,172 5.10 0.01 ± 0.00 0.06 ± 0.02 6.00
gi|296005506 Hypothetical protein 696,344 9.21 0.01 ± 0.00 0.03 ± 0.00 3.00
gi|124512392 Hypothetical protein 32,145 5.22 0.12 ± 0.00 0.25 ± 0.05 2.08
gi|124506149 RNA pseudouridylate
synthase
1,186,842 8.59 0.03 ± 0.01 0.08 ± 0.02 2.67
gi|124801199 Peptide chain release factor
subunit 1
48,034 6.59 0.02 ± 0.00 0.08 ± 0.03 4.00
gi|124512284 Hypothetical protein 117,007 8.86 0.01 ± 0.00 0.03 ± 0.00 3.00
gi|160687 Serine rich protein
homologue
110,410 5.93 0.03 ± 0.01 0.07 ± 0.02 2.33
gi|124804472 Conserved Plasmodium
protein
244,889 5.54 0.01 ± 0.00 0.02 ± 0.00 2.00
gi|124015257 Erythrocyte membrane
protein 1
252,432 5.22 0.01 ± 0.00 0.03 ± 0.01 3.00
gi|258597217 Conserved Plasmodium
protein
176,010 9.50 0.01 ± 0.00 0.02 ± 0.00 2.00
gi|124513598 DNA helicase 169,009 8.32 0.01 ± 0.00 0.02 ± 0.00 2.00
gi|124512436 Hypothetical protein 84,324 9.47 0.01 ± 0.00 0.04 ± 0.01 4.00
gi|124505687 Erythrocyte binding
antigen-181
180,922 6.16 0.04 ± 0.01 0.09 ± 0.02 2.25
03 
t
t
m
b
n
a
n
i
a
rgi|124804753 Conserved Plasmodium
protein
82,452 9.
a ND, not detectable.
he cytoplasm for degradation [23]. However, HAP cannot initiate
he degradation of native haemoglobin. Rather, it requires plas-
epsin I, II, and IV for digestion initiation. These four proteases have
een continually researched as potential targets for developing
ovel drugs against malaria parasites [24]. Although, the associ-
tion between meﬂoquine resistance and overexpression of HAP is
ot clearly understood, this protein is interesting in that it is located
n the food vacuole, which is also the site of meﬂoquine action,
nd plays a crucial role in parasite survival. Our results have also
evealed that exportin 1, a nuclease transporter, was  up-regulated0.02 ± 0.00 0.04 ± 0.01 2.00
in the meﬂoquine-resistant line. In many eukaryotes, this pro-
tein is an essential mediator for nuclear protein, mRNA, and drug
export [25]. CRM1/exportin 1 inhibition was able to sensitize drug-
resistant human myeloma cell lines and patient myeloma cells
to cancer chemotherapy drugs such as doxorubicin, bortezomib,
and carﬁlzomib. These ﬁndings support an association between
exportin 1 and drug resistance in cancer [26]. P. falciparum exportin
1 probably controls the meﬂoquine resistance phenotype via
nucleocytoplasmic export, which affects subcellular localiza-
tion, cell cycle regulation and transcription. This suggests that
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Table 2
Down-regulated proteins in meﬂoquine-sensitive and meﬂoquine-resistant P. falciparum.
Accession Protein Mass pI emPAI value Fold change
MQ  sensitive MQ resistant
gi|124513762 Thioredoxin-related protein 23,972 9.44 1.42 ± 0.06 0.34 ± 0.07 −4.18
gi|124810210 40S ribosomal protein S3 24,652 10.2 0.78 ± 0.03 0.33 ± 0.05 −2.36
gi|124513590 Phosphoethanolamine N-methyltransferase 31,024 5.43 2.55 ± 0.08 0.41 ± 0.03 −6.22
gi|124506992 S-adenosylmethionine synthetase 44,816 6.28 0.62 ± 0.03 0.08 ± 0.01 −7.75
gi|124511826 Histone H2B 13,755 10.27 7.20 ± 0.37 1.86 ± 0.12 −3.87
gi|124803615 Casein kinase II, alpha subunit 39,865 8.9 0.31 ± 0.09 0.09 ± 0.01 −3.44
gi|296005005 Hypothetical protein 37,477 4.13 0.46 ± 0.04 0.21 ± 0.06 −2.19
gi|124801997 60S ribosomal protein L13 23,739 10.19 0.35 ± 0.01 0.16 ± 0.03 −2.19
gi|124511970 40S ribosomal protein S5 21,849 9.67 0.62 ± 0.03 0.18 ± 0.02 −3.44
gi|3242984 Merozoite capping protein-1 38,293 9.33 0.21 ± 0.01 0.10 ± 0.02 −2.10
gi|124505943 Hypothetical protein 30,696 9.47 0.59 ± 0.03 0.26 ± 0.04 −2.27
gi|86171362 Pyridoxine biosynthetic enzyme pdx1 32,992 6.76 0.54 ± 0.02 0.11 ± 0.02 −4.91
gi|124513178 Small GTPase Rab11 24,737 8.97 0.33 ± 0.01 0.15 ± 0.03 −2.20
gi|829215 Unnamed protein product 10,747 5.04 0.88 ± 0.00 0.37 ± 0.05 −2.38
gi|124512798 40S ribosomal protein S7 22,467 9.81 0.37 ± 0.00 0.17 ± 0.03 −2.18
gi|82541094 Histone 3 15,437 11.14 0.57 ± 0.03 0.25 ± 0.01 −2.28
gi|124810024 Conserved Plasmodium protein, unknown function 40,043 9.6 0.31 ± 0.01 NDa NDa
gi|86171008 Organic anion transporter 96,918 5.59 5.13 ± 0.33 1.48 ± 0.07 −3.47
gi|124513666 Hypothetical protein 42,133 7.14 0.41 ± 0.10 0.19 ± 0.01 −2.16
gi|124504989 Formate-nitrate transporter 34,436 8.74 0.23 ± 0.03 0.11 ± 0.01 −2.09
gi|124513774 Hypothetical protein 32,763 9.22 0.24 ± 0.06 0.12 ± 0.02 2.00
gi|124505615 Plasmodium exported protein (PHISTb) 35,939 8.75 0.22 ± 0.04 0.10 ± 0.02 −2.20
gi|21591743 Rhoptry-associated protein 3 46,947 8.52 0.17 ± 0.00 NDa NDa
gi|124505467 Small GTP-binding protein sar1 22,006 6.76 0.38 ± 0.09 0.17 ± 0.04 −2.24
gi|124805752 Glutathione peroxidase 23,937 8.99 0.34 ± 0.03 0.16 ± 0.05 −2.13
gi|552237 Ubiquitin 8659 6.79 1.16 ± 0.05 NDa NDa
gi|124504725 N-ethylmaleimide-sensitive fusion protein 89,078 6.31 0.04 ± 0.00 0.02 ± 0.00 −2.00
gi|124507271 Hypothetical protein 45,472 9.71 0.48 ± 0.03 0.17 ± 0.03 −2.82
gi|124512998 Hypothetical protein 277,526 7.79 0.04 ± 0.00 0.01 ± 0.00 −4.00
gi|309688 PfsXLX 377,125 5.71 0.03 ± 0.00 0.01 ± 0.00 −3.00
gi|467989 Adenine nucleotide translocase 33,691 9.68 0.23 ± 0.04 0.11 ± 0.03 −2.09
gi|124514090 Hypothetical protein 62,438 9.23 0.14 ± 0.02 0.06 ± 0.01 −2.33
gi|258597207 Conserved Plasmodium protein 30,641 4.98 0.42 ± 0.03 0.12 ± 0.02 −3.50
a ND, not detectable.
Fig. 4. Extracted ion chromatograms of a pfmdr1 peptide (FAAIDEFIESLPNKYDTNVGPYGK) at m/z 896.7 from three biological replicates. MQS1, MQS2, MQS3, MQR1, MQR2 and
MQR3  are meﬂoquine-sensitive P. falciparum 1, meﬂoquine-sensitive P. falciparum 2, meﬂoquine-sensitive P. falciparum 3, meﬂoquine-resistant P. falciparum 1, meﬂoquine-
resistant P. falciparum 2 and meﬂoquine-resistant P. falciparum 3, respectively.
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QR3  are meﬂoquine-sensitive P. falciparum 1, meﬂoquine-sensitive P. falciparum 2
esistant P. falciparum 2 and meﬂoquine-resistant P. falciparum 3, respectively.
ukaryotic translation initiation factor 3 (eIF-3), which plays a role
n protein synthesis in eukaryotes, is up-regulated in meﬂoquine-
esistant parasites. In a quantitative proteomic analysis, eIF-3
howed higher expression levels in amphotericin-B-resistant
eishmania infantum [27]. Additionally, eLF-3 was  shown to be
p-regulated in human lymphoblastic leukaemia cells exhibit-
ng cross-resistance to prednisolone, vincristine, asparaginase and
aunorubicin by a genome-wide screening approach [28]. Corre-
ating to the role of eIF-3 in other organisms, meﬂoquine-resistant
. falciparum may  change its regulation of protein synthesis
hrough eIF-3. Peptidyl-prolyl cis-trans isomerase, which accel-
rates the folding of other proteins, was an up-regulated proteinm/z 896.7 from three biological replicates. MQS1, MQS2, MQS3, MQR1, MQR2 and
oquine-sensitive P. falciparum 3, meﬂoquine-resistant P. falciparum 1, meﬂoquine-
found in this study. Peptidyl-prolyl cis-trans isomerase in Saccha-
romyces cerevisiae mediates sensitivity to the macrolide antifungal
agent, rapamycin [29]. Up-regulation of peptidyl-prolyl cis-trans
isomerase has also been seen in gemcitabine-resistant human pan-
creatic cancer cells [30]. Overexpression of peptidyl-prolyl cis-trans
isomerase induced chemoresistance to cisplatin; however, when it
was knocked down cisplatin sensitivity increased [31]. As the above
studies indicate, several attempts have been made to explain the
crucial role played by this protein in drug resistance; hence, there
is now interest in studying its potential role in drug resistance
in P. falciparum. SERP, which contains a cysteine-type peptidase
motif, was  also overexpressed in meﬂoquine-resistant parasites.
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Fig. 6. Differences in the expression levels of nine marker genes in meﬂoquine-sensitive and -resistant P. falciparum quantiﬁed using proteomics and qRT-PCR techniques.
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mn S. cerevisiae,  the MLF3 gene encoding a SERP conferred leﬂuno-
ide resistance when its copy number increased [32]. As indicated
y its role in drug resistance in yeast, SERP may  also have an
mportant molecular function involving meﬂoquine resistance in
. falciparum.  From the proteomics result, it appears that Exp-1
as also overexpressed in the meﬂoquine-resistant parasites. A
ransmembrane protein and P. falciparum antigen, Exp-1 is trans-
orted to the parasitophorous vacuole membrane and to red blood
ell (RBC) cytoplasm [33]. Generally, the mechanical properties of
BC membranes are altered during infection with malaria para-
ites, thereby enabling the transport of a range of nutrients and
mall molecules. This process is established through the insertion of
arasite exported proteins into the RBC membrane [34]. There has
een little discussion about the function of Exp-1 in malaria para-
ites. However, it is possibly involved in meﬂoquine transportation
y mediating RBC membrane permeability. Our proteomic ﬁndings
ave also provided evidence that the ATP synthase beta chain is up-
egulated in meﬂoquine resistant parasites. Despite this protein
eing a mitochondrial precursor in P. falciparum,  it has also been
dentiﬁed in the food vacuole of the parasite [35]. ATP synthase
eta chain assembles with other subunits to form a large complex
hat is essential for parasite survival [36]. Commonly, ATP synthase
s an ATP binding cassette protein member involved in mediating
ubstrate transport across membranes against a concentration gra-
ient. This protein may  confer in the parasite the ability to transport
eﬂoquine. Proteomics showed that phospholipid scramblase 1
as also overexpressed. However, thus far very little attention has
een paid to phospholipid scramblase 1 of P. falciparum.  Phospho-
ipid scramblase 1 of other organisms mediates the translocation of
hospholipids upon binding of calcium ions to membranes. Human
hospholipid scramblase 1 can modulate the response to arsenic
rioxide (As2O3) during ovarian cancer treatment [37]. In malaria
arasites, phospholipid scramblase 1 might play a role in modu-
ating the meﬂoquine response. Enolase, a glycolytic enzyme, was
lso up-regulated in meﬂoquine resistant line. In lymphoma cell,
nolase was found to participate in the drug resistance. Inhibition
f enolase expression is a new strategy for reducing drug resistance
38]. Enolase of P. falciparum might involve in meﬂoquine resistant
echanisms. In case of this protein might not involve in meﬂoquineresistance. It is possible to play a role in balancing general cellular
function to maintain parasite survival.
Based on the data we obtained on protein function and our
literature reviews, we selected nine up-regulated proteins (Pgh1,
HAP, exportin 1, eukaryotic translation initiation factor 3, peptidyl-
prolyl cis-trans isomerase, SERP, Exp-1, ATP synthase beta chain
and phospholipid scramblase 1) for further validation using reverse
transcriptase qPCR.
3.2. Relative gene expression levels in meﬂoquine-sensitive and
-resistant P. falciparum using reverse transcriptase qPCR
To conﬁrm the LC–MS/MS results, qRT-PCR was used to exam-
ine gene transcription. Nine up-regulated expressed genes from
meﬂoquine-sensitive and -resistant P. falciparum were selected
according to their potentially interesting functions. All primers
used for these experiments were designed from the sequences
available at NCBI GenBank. The gene-speciﬁc primers are listed in
Supplementary Table 4. Target genes were ampliﬁed in triplicate
and beta-tubulin was the reference gene. As shown by the data in
Table 1 and conﬁrmed by the data in Fig. 6, the multidrug resis-
tance protein Pgh1 was upregulated in the meﬂoquine-resistant
parasites. The data show that pfmdr1 has an average of 3 copy
numbers related to its transcription and translation, while the pro-
teomics and RT-qPCR data showed 8.5-fold (±3.69) and 7.67-fold
(±0.34) increases, respectively. The other eight genes also showed
evidence of higher expression levels in the meﬂoquine-resistant
parasites. In the presence of meﬂoquine, the expression levels of the
nine candidate markers increased further. Therefore, GeLC–MS/MS
based proteomics combined with emPAI label-free quantiﬁcation
was able to identify and quantify the biological samples accu-
rately. Hence, this technique can generate a marker library for
meﬂoquine resistance. While some marker proteins may  not be
involved in the meﬂoquine resistance mechanism directly, they are
probably related to survival processes in the parasite. Meﬂoquine
resistance protein markers can be uncharacterized proteins with
no known function, making the resistance mechanisms more dif-
ﬁcult to understand. However, candidate markers from proteomic
nal of 
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ibraries provide a fascinating avenue for exploration of their rela-
ionships with meﬂoquine resistance mechanisms in P. falciparum.
. Conclusion
In this investigation, the aim was to assess the meﬂoquine
esistance mechanisms of P. falciparum using GeLC–MS/MS-based
roteomics combined with emPAI label-free quantiﬁcation. The
ndings suggest that meﬂoquine resistance might stem from mul-
ifactorial traits involving up- and down-regulation of proteins
ith functions in transportation and gene regulation processes. The
ultidrug resistance protein Pgh1 was substantially up-regulated
n the meﬂoquine-resistant parasite line, conﬁrming that it may
lay an important role in meﬂoquine resistance mechanisms.
owever, several other proteins identiﬁed for the ﬁrst time in
he present study also have the potential to enhance the meﬂo-
uine resistance phenotype. Therefore, further investigation and
xperimentation with proteins differentially expressed between
eﬂoquine-sensitive and -resistant parasites are strongly recom-
ended.
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